表格6-K
美国证券及交易所委员会
华盛顿特区20549
外国私人发行人报告
根据第13a-16或第15d-16条规则
1934年证券交易所法案
2024年10月
委员会档案编号：001-38757
武田制药有限公司
(注册人名称之英文翻译)
日本桥本町二丁目1-1
东京103-8668中央区
日本
(总部办公地址)
请勾选表明登记人是否提交或将提交以20-F表或40-F表作封面的年度报告。
20-F表格 ☒ 40-F表格 ☐
如果申报人根据条例 S-T 规则 101(b)(1) 允许，以纸本方式提交表格 6-K，请打勾： ☐
如果发出申报书6-K是根据Regulation S-T Rule 101(b)(7)允许的纸上提交，请用勾选印记表示： ☐
此表格提供的资讯：
展览
签名
根据《证券交易法》的要求，申报人已经授权签署此报告，且得到了授权。
| 武田制药有限公司 | |||||||||||
| 日期：2024年10月31日 | 作者： | /s/ 武田典政 | |||||||||
武田典政 首席会计官和公司控制器 | |||||||||||
新闻公告
关于2024财年（IFRS）合并财务预测修正的通知
2024年10月31日，日本大阪 武田（TSE：4502 / 纽交所：TAK）今日宣布了截至2025年3月31日（FY2024）的全年合并财务预测修订如下。
1.截至2025年3月31日财政年度终了时的全年综合财务预测已修订
(百万日元)
营业收入 | 营运 利润 | 营业收入之前 所得税前获利 | 应归属净利润 原本拥有者的 该公司 | 基本盈利 每股盈利 | |||||||||||||
原始预测 (A)* | 4,350,000 | 225,000 | 55,000 | 58,000 | 36.70日圆 | ||||||||||||
修订预测 (B) | 4,480,000 | 265,000 | 93,000 | 68,000 | 43.03日圆 | ||||||||||||
差异 (B-A) | 130,000 | 40,000 | 38,000 | 10,000 | ― | ||||||||||||
更改 % | 3.0% | 17.8% | 69.1% | 17.2% | ― | ||||||||||||
* 2024年5月9日宣布。
(百万日元)
核心营收 | 核心 营运 利润 | 核心每股收益 | |||||||||
原始预测（A）* | 4,350,000 | 1,000,000 | 431 日元 | ||||||||
修订预测（B） | 4,480,000 | 1,050,000 | 456日圆 | ||||||||
（b-A）的差异 | 130,000 | 50,000 | ― | ||||||||
更改 % | 3.0% | 5.0% | ― | ||||||||
* 2024年5月9日宣布。
（注意）有关核心财务指标的定义，请参阅附于盈利报告的财务附录中的「非IFRS财务指标及美元方便换算的定义和解释」。
2.修订原因
武田预计2024年的营业收入将达到44800亿日元，比原先预测增加1300亿日元，增幅为3.0%。主要原因是在美国Vyvanse失去专利后，所预期的通用药物侵蚀较轻微，以及其他业务动能以及对外汇汇率假设的整体有利变化。
核心营业收入预测已经以与营业收入预测相同的方式进行修订。
预计营业利润将从原始预测的JPY 2650亿增加JPY 400亿，增长17.8％，这反映了由于美国低于预期的通用侵蚀对VYVANSE产生的积极影响。 其他产品、增量营业费用和外币汇率的不利影响部分抵销了这一增长。
核心营业利润，不包括与武田核心业务趋势和业务表现无关的影响，预计达到1.05兆日圆，增加5百亿日圆，增幅为5.0%。
预计本年度净利润（归属于公司股东）将达到680亿日元，较原始预测增加100亿日元，增幅为17.2%。预计税前利润将增加380亿日元，增幅为69.1%，主要反映营业利润的增加。尽管预计这种税前利润增加将部分被较高的税费抵销，主要是由于递延税资产减值所致，导致预期有效税率约为27%。
预计每股收益为JPY 43.03，增加JPY 6.33，即17.2％，核心每股收益预计为JPY 456，增加JPY 26，即5.9％。
3.管理指引 至2025年3月31日止财政年度
武田以在恒定汇率（CER）基础上的核心营收、核心营业利润和核心每股收益变化作为其管理指引。截至2025年3月31日（截至2024年度）的整年管理指引已从2024年5月9日公布的原管理指引进行修订，具体如下：
CER变动%
原始管理指导 (2024年5月9日) | 修订后管理指导 (2024年10月31日) | |||||||
核心营收 | 持平至稍微下降 | 持平至稍微增加 | ||||||
核心营业利润 | 大约下跌百分之十 | 中位数字百分之几下跌 | ||||||
核心每股收益 | 中位数字十位百分之几下跌 | 大约下跌百分之十 | ||||||
有关武田药品的事项
武田致力于为人们创造更健康的生活和更美好的未来。我们的目标是在消化道和炎症、罕见疾病、血浆衍生治疗、肿瘤学、神经科学和疫苗等核心治疗和业务领域发现和提供改变生活的治疗方法。与我们的合作伙伴共同努力，通过我们丰富多样的管线改善患者体验，推动治疗期权的新领域。作为一家以价值为基础、以研发为驱动的生物制药公司，总部位于日本，我们以对患者、我们的人员和地球的承诺为指导。我们在大约80个国家和地区拥有员工，他们受我们的宗旨驱使，承担了已经为我们定义了两个世纪的价值观。欲了解更多信息，请造访 www.takeda.com.
联络人
投资者关系 克里斯多福·奥赖利 christopher.oreilly@takeda.com +81 (0) 3-3278-2543 | 媒体联系 布伦丹·詹宁斯 brendan.jennings@takeda.com +81 (0) 80-2705-8259 (在 日本 业务时间之外) M媒体关系media_relations@takeda.com | ||||
重要通知
就本通知而言，“新闻稿”指的是本文件、任何口头发表、任何问答环节以及武田制药公司（“武田”）有关本新闻稿的任何书面或口头材料。本新闻稿（包括任何口头简报以及相关之问答环节）并非旨在构成、代表或成为任何要约、邀请或征求购买、另行取得、认购、交换、卖出或其他处置任何证券的一部分或其中。本新闻稿中并未透露任何股份或其他证券以供公众认购。除依据已修订的1933年美国证券法或其豁免条款登记之情况外，不得透过本新闻稿在美国进行证券发行。本新闻稿之提供（连同可能提供予接收者的任何进一步资讯）须受其仅供接收者仅供信息之条件控制（并非用于评估任何投资、收购、处置或任何其他交易）。任何不遵守这些限制可能构成对适用证券法的违反。
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or
any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Financial Information and Non-IFRS Measures
Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).
This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our investor presentation of our Q2 FY2024 financial results (available at www.takeda.com/investors).
The usefulness of Core Financial Measures to investors has significant limitations including, but not limited to, (i) they are not necessarily identical to similarly titled measures used by other companies, including those in the pharmaceutical industry, (ii) they exclude financial information and events, such as the effects of non-cash expenses such as dispositions or amortization of intangible assets, that some may consider important in evaluating Takeda’s performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future (however, it is Takeda’s policy not to adjust out normal, recurring cash operating expenses necessary to operate our business) and (iv) they may not include all items which investors may consider important to an understanding of our results of operations, or exclude all items which investors may not consider to be so.
###